What is Circassia?
Founded in 2006 and headquartered in Oxford, UK, Circassia operates as a specialized diagnostics and management firm with a primary focus on asthma care. The company occupies a distinct niche in the life sciences sector, leveraging advanced research to address the unmet needs of patients suffering from chronic respiratory conditions. By integrating diagnostic precision with management strategies, Circassia aims to improve patient outcomes and streamline clinical workflows. Its market position is bolstered by a history of high-profile institutional support, which has provided the necessary resources to transition from academic innovation to a mature, enterprise-level entity capable of influencing standard-of-care protocols in the respiratory health domain.
How much funding has Circassia raised?
Circassia has raised a total of $667.3M across 7 funding rounds:
Series A
$7.5M
Series B
$21.8M
Series C
$25M
Series D
$98M
Other Financing Round
$154M
Series E
$19M
Stock Offering
$342M
Series A (2007): $7.5M with participation from Undisclosed
Series B (2008): $21.8M led by Imperial Innovations, Invesco, Lansdowne Partners, and Goldman Sachs
Series C (2009): $25M supported by Imperial Innovations, Lansdowne Partners, and Invesco
Series D (2011): $98M featuring Imperial Innovations and Invesco
Other Financing Round (2012): $154M backed by Invesco and Imperial Innovations
Series E (2012): $19M with participation from Invesco and Imperial Innovations
Stock Issuance/Offering (2015): $342M led by Undisclosed
Key Investors in Circassia
Imperial Innovations
A technology commercialization firm linked to Imperial College London, specializing in translating world-class research in science, engineering, and medicine into viable commercial enterprises.
Invesco
A global independent investment management firm that provides a comprehensive range of equity, fixed income, and alternative investment strategies to institutional and retail clients.
Lansdowne Partners
A London-based investment management partnership focused on delivering superior long-term returns through disciplined, research-intensive investment strategies.
What's next for Circassia?
Looking ahead, the strategic deployment of the $342M capital is expected to prioritize the acceleration of product commercialization and the strengthening of the company's diagnostic pipeline. As Circassia moves beyond its foundational growth phase, the focus will likely shift toward maximizing market penetration and optimizing the delivery of its asthma management solutions. The firm remains well-positioned to leverage its established relationships with top-tier investment partners to navigate the regulatory and competitive challenges inherent in the global diagnostics market. Future growth will be defined by the company's ability to translate its research-driven heritage into sustainable, long-term value for stakeholders and patients alike.
See full Circassia company page
